Roche: acquires Poseida Therapeutics

(CercleFinance.com) - Roche announced that it has entered into a definitive agreement to acquire Poseida Therapeutics, a public clinical-stage biopharmaceutical company pioneering the field of donor-derived CAR-T cell therapies.


Based in San Diego, California, Poseida's R&D portfolio includes preclinical and clinical ready-to-use (also known as allogeneic) CAR-T therapies in several therapeutic areas, including hematological malignancies, solid tumors and autoimmune diseases, as well as manufacturing capabilities and technology platforms.

This acquisition builds on the existing partnership between Roche and Poseida following the collaboration and licensing agreement established in 2022 , which focuses on the development of ready-to-use CAR-T cell therapies to address the medical needs of patients with hematological diseases.

This promising acquisition will enable us to continue our progress in allogeneic cell therapy while building on our existing successful partnership with Poseida, Roche said.

It adds that it is very encouraged by the early clinical data, and this acquisition builds on our joint progress to catalyze the development of potentially innovative, first-in-class cell therapies in oncology, immunology and neurology.


Copyright (c) 2024 CercleFinance.com. All rights reserved.